RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/32678423http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/32678423http://www.w3.org/2000/01/rdf-schema#comment"The activated form of coagulation factor XIII (FXIII-A2B2), FXIII-A*, is a hemostatic enzyme essential for inhibiting fibrinolysis by irreversibly crosslinking fibrin and antifibrinolytic proteins. Despite its importance, there are no modulatory therapeutics. Guided by the observation that humans deficient in FXIII-B have reduced FXIII-A without severe bleeding, we hypothesized that a suitable small interfering RNA (siRNA) targeting hepatic FXIII-B could safely decrease FXIII-A. Here we show that knockdown of FXIII-B with siRNA in mice and rabbits using lipid nanoparticles resulted in a sustained and controlled decrease in FXIII-A. The concentration of FXIII-A in plasma was reduced by 90% for weeks after a single injection and for more than 5 months with repeated injections, whereas the concentration of FXIII-A in platelets was unchanged. Ex vivo, crosslinking of α2-antiplasmin and fibrin was impaired and fibrinolysis was enhanced. In vivo, reperfusion of carotid artery thrombotic occlusion was also enhanced. Re-bleeding events were increased after challenge, but blood loss was not significantly increased. This approach, which mimics congenital FXIII-B deficiency, provides a potential pharmacologic and experimental tool to modulate FXIII-A2B2 activity."xsd:string
http://purl.uniprot.org/citations/32678423http://purl.org/dc/terms/identifier"doi:10.1182/blood.2020004976"xsd:string
http://purl.uniprot.org/citations/32678423http://purl.uniprot.org/core/author"Leung J."xsd:string
http://purl.uniprot.org/citations/32678423http://purl.uniprot.org/core/author"Conway E.M."xsd:string
http://purl.uniprot.org/citations/32678423http://purl.uniprot.org/core/author"Palumbo J.S."xsd:string
http://purl.uniprot.org/citations/32678423http://purl.uniprot.org/core/author"Russell H.M."xsd:string
http://purl.uniprot.org/citations/32678423http://purl.uniprot.org/core/author"Sutherland M.R."xsd:string
http://purl.uniprot.org/citations/32678423http://purl.uniprot.org/core/author"Owens A.P."xsd:string
http://purl.uniprot.org/citations/32678423http://purl.uniprot.org/core/author"Meixner S.C."xsd:string
http://purl.uniprot.org/citations/32678423http://purl.uniprot.org/core/author"Kastrup C.J."xsd:string
http://purl.uniprot.org/citations/32678423http://purl.uniprot.org/core/author"Cullis P.R."xsd:string
http://purl.uniprot.org/citations/32678423http://purl.uniprot.org/core/author"Strilchuk A.W."xsd:string
http://purl.uniprot.org/citations/32678423http://purl.uniprot.org/core/author"Safikhan N.S."xsd:string
http://purl.uniprot.org/citations/32678423http://purl.uniprot.org/core/author"Kulkarni J.A."xsd:string
http://purl.uniprot.org/citations/32678423http://purl.uniprot.org/core/author"Pryzdial E.L.G."xsd:string
http://purl.uniprot.org/citations/32678423http://purl.uniprot.org/core/author"van der Meel R."xsd:string
http://purl.uniprot.org/citations/32678423http://purl.uniprot.org/core/date"2020"xsd:gYear
http://purl.uniprot.org/citations/32678423http://purl.uniprot.org/core/name"Blood"xsd:string
http://purl.uniprot.org/citations/32678423http://purl.uniprot.org/core/pages"2946-2954"xsd:string
http://purl.uniprot.org/citations/32678423http://purl.uniprot.org/core/title"Sustained depletion of FXIII-A by inducing acquired FXIII-B deficiency."xsd:string
http://purl.uniprot.org/citations/32678423http://purl.uniprot.org/core/volume"136"xsd:string
http://purl.uniprot.org/citations/32678423http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/32678423
http://purl.uniprot.org/citations/32678423http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/32678423
http://purl.uniprot.org/uniprot/#_Q07968-mappedCitation-32678423http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/32678423